The 2-Minute Rule for ABBV-744 in the treatment of drug-resistant cancers
In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right until ailment progression or even the members are unable to tolerate the study drugs.and after that boost H3K27Ac at this location. Chromatin hyperacetylation could raise the accessibi